The Street's worry is simple: if a compounding pharmacy can mix up a copy of a blockbuster obesity drug for a fraction of the price, the branded franchise is in trouble. It is a real concern. It is also more bounded than the coverage implies, and the patent record is where you see the boundary.
Here's the single fact that reframes it: compounding is mostly a regulatory exception, not a competing product class. It is largely permitted when a drug is in shortage, and it narrows or closes when supply catches up. It rides on a gap, not on a right. Meanwhile the incumbents keep tightening the patent fence.
The 2025 filings show that fence going up. Publication US20250367260A1 covers tirzepatide compositions and a preparation method — claims aimed squarely at how the actual drug is made and formulated. Lilly's granted incretin estate, including US12252524B2 on GIP/GLP1 co-agonist compounds, covers the molecule and its formulations directly.
Acknowledge the bull case for the disruptors: when a drug is in shortage and demand is enormous, compounded versions genuinely reach patients the brand can't supply, and they genuinely pressure price perception. That happened, and it mattered.
But read the risk factors the other way. A composition patent doesn't care that a copy is cheaper — it cares that it's covered. As shortages ease and the patent estate thickens with new composition and method claims, the legal room for large-scale compounded copies shrinks. The exception was always conditional.
So the reality check: the compounding threat to GLP-1 drugs is real during shortage windows and overstated as a permanent force. The 2025 patent record — fresh composition and co-agonist claims — is the incumbents methodically closing the gap the shortage opened. The cliff isn't compounding; it's the eventual patent expiry, and that's still being pushed outward.